Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Up 55.1% in October

Atyr PHARMA INC (NASDAQ:ATYR) was the recipient of a large increase in short interest in October. As of October 31st, there was short interest totalling 1,660,000 shares, an increase of 55.1% from the October 15th total of 1,070,000 shares. Based on an average daily volume of 761,100 shares, the days-to-cover ratio is currently 2.2 days. Approximately 2.0% of the shares of the stock are short sold.

Atyr PHARMA Stock Up 0.9 %

Shares of NASDAQ ATYR opened at $3.52 on Thursday. The company’s fifty day moving average is $2.40. Atyr PHARMA has a 12 month low of $1.09 and a 12 month high of $3.80. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41.

Atyr PHARMA (NASDAQ:ATYR) last released its earnings results on Thursday, November 7th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). Equities research analysts forecast that Atyr PHARMA will post -0.89 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ATYR shares. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research note on Tuesday, October 29th. Wells Fargo & Company assumed coverage on shares of Atyr PHARMA in a report on Friday, October 4th. They issued an “overweight” rating and a $17.00 price target for the company. Jefferies Financial Group began coverage on shares of Atyr PHARMA in a research note on Thursday, September 5th. They issued a “buy” rating and a $9.00 price objective on the stock. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $16.00 target price on shares of Atyr PHARMA in a research note on Wednesday, August 14th.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.